首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷癌症個人化醫學分子呈像/呈影劑核子醫學

市場調查報告書

商品編碼

1909170

治療診斷學市場規模、佔有率及成長分析（依產品、技術、疾病、最終用戶及地區分類）－2026-2033年產業預測

Theranostics Market Size, Share, and Growth Analysis, By Product, By Technology (Molecular Imaging, Radioligand Therapy), By Disease, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月02日 | 出版商:

SkyQuest | 英文 187 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球治療診斷學市場規模將達到 25 億美元，到 2025 年將達到 28.3 億美元，到 2033 年將達到 78.1 億美元，在預測期（2026-2033 年）內，複合年成長率將達到 13.5%。

全球治療診斷學市場正經歷強勁成長，這主要得益於人們對個人化醫療日益成長的需求以及包括癌症和心血管疾病在內的慢性病發病率的上升。這個創新領域將診斷和治療功能整合於單一平台，有助於提高治療效果並降低醫療成本。影像診斷技術的進步以及標靶藥物遞送生物標記的開發，正在拓展治療診斷學在已開發經濟體和新興經濟體的應用範圍。然而，挑戰依然存在，包括高昂的研發成本、複雜的法規環境以及低收入族群認知度不足。此外，有限的保險覆蓋範圍和對專用基礎設施的需求也阻礙了治療診斷學解決方案融入傳統臨床實踐，凸顯了政策改革和策略夥伴關係對於克服這些障礙的必要性。

全球治療診斷學市場促進因素

全球治療診斷學市場成長的主要驅動力之一是個人化醫療的日益普及。這種方法強調根據個體的基因和分子特徵量身定做治療策略，將診斷和治療流程結合。這種對個人化治療的關注使醫療服務提供者能夠在提高療效的同時，最大限度地減少患者的副作用。這種向整合解決方案的轉變不僅改善了治療結果，還提高了患者照護的整體質量，因此個人化醫療成為治療診斷學市場擴張的關鍵驅動力。

限制全球治療診斷學市場發展的因素

全球治療診斷學市場受到許多重大財務障礙的限制，影響了其可近性。先進成像技術、專用試劑和合格人員的高昂成本構成了複雜的成本結構。這種經濟負擔對醫療資源匱乏地區和農村地區的影響尤其嚴重，限制了他們獲得治療診斷學影像產品的機會。此外，這些成本還會加重醫療系統的負擔，並使報銷模式變得複雜。政治上的不確定性以及治療診斷學解決方案融入標準臨床實踐的潛在延遲進一步加劇了這種情況，最終限制了市場成長和這些創新治療方法的廣泛應用。

全球治療診斷學市場趨勢

將人工智慧 (AI) 整合到診斷和治療系統中是全球治療診斷學市場的一大趨勢。這種創新組合透過 AI 輔助診斷，有效調整治療方案以適應個別患者，從而增強了個人化醫療。 AI 對臨床、治療和診斷數據的分析有助於高效解讀醫學影像，並提高治療反應的預測準確性。因此，這一新興領域不僅加速了精準醫療的發展，而且透過即時、數據驅動的策略，優先考慮患者療效，從而推動複雜疾病的管理，在全球範圍內改變著醫療保健模式。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Bayer AG
GE Healthcare
Siemens Healthineers
Thermo Fisher Scientific Inc.
Abbott Laboratories
Novartis AG
Telix Pharmaceuticals Limited
Curium Pharma
Advanced Accelerator Applications（AAA）
Bracco Imaging SpA
Lantheus Holdings
NanoString Technologies, Inc.
Roche Holding AG
Qiagen NV
Illumina Inc.
Myriad Genetics, Inc.
AbbVie Inc.
Philips Healthcare
Endocyte, Inc.
NorthStar Medical Radioisotopes LLC

結論與建議

簡介目錄

Product Code: SQMIG35G2362

Global Theranostics Market size was valued at USD 2.5 Billion in 2024 and is poised to grow from USD 2.83 Billion in 2025 to USD 7.81 Billion by 2033, growing at a CAGR of 13.5% during the forecast period (2026-2033).

The global theranostics market is experiencing robust growth driven by a rising demand for personalized medicine and the increasing prevalence of chronic diseases, including cancer and cardiovascular disorders. This innovative field, which combines diagnostic and therapeutic functions into a single platform, enhances treatment efficacy while fostering cost savings in healthcare. Advancements in imaging technologies and biomarkers for targeted drug delivery are broadening the scope of theranostic applications across both developed and emerging markets. However, the market faces challenges such as high development costs, complex regulatory environments, and limited awareness in low-income regions. Additionally, restricted reimbursement and the need for specialized infrastructure hinder the integration of theranostic solutions into conventional clinical practices, emphasizing the necessity for policy reforms and strategic partnerships to overcome these obstacles.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Theranostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Theranostics Market Segments Analysis

Global Theranostics Market is segmented by Product, Technology, Disease, End-User and region. Based on Product, the market is segmented into Diagnostic Imaging Agents, Radiopharmaceuticals & Targeted Therapeutics, IVD/Biomarker Screening Kits and Software & Services. Based on Technology, the market is segmented into Molecular Imaging (PET/SPECT), Radioligand Therapy, Nanoparticle-based Theranostics and Biomarker-driven Companion Diagnostics. Based on Disease, the market is segmented into Oncology, Neurology, Cardiovascular Diseases, Immunological/Inflammatory Disorders and Others. Based on End-User, the market is segmented into Hospitals & Cancer Treatment Centres, Diagnostic Laboratories, Research & Academic Institutes and Theranostics Centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Theranostics Market

A significant catalyst for growth in the global theranostics market is the increasing adoption of personalized medicine. This approach emphasizes tailored treatment strategies by combining diagnostic and therapeutic processes that align with individual genetic and molecular characteristics. By focusing on personalized therapies, healthcare providers can achieve enhanced therapeutic outcomes while minimizing adverse effects for patients. This shift towards integrated solutions not only improves treatment efficacy but also elevates the overall quality of patient care, making personalized medicine a key driving force behind the expansion of the theranostics market.

Restraints in the Global Theranostics Market

The Global Theranostics market is hindered by significant financial barriers that impact accessibility. The high expenses involved in acquiring advanced imaging technologies, specialized reagents, and qualified personnel create a challenging cost structure. This financial burden particularly affects underserved and rural regions, limiting their access to theranostic imaging products. Additionally, these costs can strain healthcare systems and complicate reimbursement models. Political uncertainties and the potential for delays in the integration of theranostic solutions into standard clinical practice further exacerbate the situation, ultimately restricting the market's growth and the widespread adoption of these innovative therapies.

Market Trends of the Global Theranostics Market

The global theranostics market is witnessing a significant trend driven by the integration of artificial intelligence into diagnostic and therapeutic systems. This innovative combination enhances personalized medicine by enabling AI-assisted diagnosis that tailors treatments to individual patients effectively. The AI-powered analysis of clinical, therapeutic, and diagnostic data facilitates the efficient interpretation of medical images and improves predictions regarding therapy responses. As a result, this burgeoning field is not only accelerating the evolution of precision medicine but also advancing the management of complex diseases through real-time, data-driven strategies that prioritize patient outcomes, thereby reshaping healthcare paradigms on a global scale.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Assessment
Regulatory Landscape

Global Theranostics Market Size by Product & CAGR (2026-2033)

Market Overview
Diagnostic Imaging Agents
Radiopharmaceuticals & Targeted Therapeutics
IVD/Biomarker Screening Kits
Software & Services

Global Theranostics Market Size by Technology & CAGR (2026-2033)

Market Overview
Molecular Imaging (PET/SPECT)
Radioligand Therapy
Nanoparticle-based Theranostics
Biomarker-driven Companion Diagnostics

Global Theranostics Market Size by Disease & CAGR (2026-2033)

Market Overview
Oncology
Neurology
Cardiovascular Diseases
Immunological/Inflammatory Disorders
Others

Global Theranostics Market Size by End-User & CAGR (2026-2033)

Market Overview
Hospitals & Cancer Treatment Centres
Diagnostic Laboratories
Research & Academic Institutes
Theranostics Centres

Global Theranostics Market Size & CAGR (2026-2033)

North America (Product, Technology, Disease, End-User)
- US
- Canada
Europe (Product, Technology, Disease, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Technology, Disease, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Technology, Disease, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Technology, Disease, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Telix Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curium Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advanced Accelerator Applications (AAA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bracco Imaging S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NanoString Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Philips Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Endocyte, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NorthStar Medical Radioisotopes LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments